Target binding was blocked most (40% reduction) after a short, 5 min, blocking dose pretreatment with a lesser blockade observed 4 h after pretreatment and no appreciable change observed 24 h after nonradioactive martinostat pretreatment (n = 1 rat/blocking condition; 5 min time point same data as in Figure 2C,D).
After nonspecific binding was blocked, the slides were incubated with NDRG2 antibody (1 200; Abnova, Taipei, Taiwan) or GLUT1 antibody (1 200; Santa Cruz Biotechnology, Santa Cruz, CA, USA) in phosphate-buffered saline (PBS) at 4°C overnight in a humidified container.
C/EBPβ might therefore stimulate the promoter activity at the Runx motif as a co-activator of Runx2, even after the innate binding was blocked, although our luciferase assay and EMSA so far have failed to find evidence of this.
After non-specific binding was blocked with 5 % BSA in PBS for 30 min, sections were incubated with primary antibodies of CK (1 50), VIM (1 50), E-cad (1 80) and Snail1 (1 100) overnight at 4 °C.
After cooling, nonspecific binding was blocked with diluted serum (goat IgG ABC kit; Vectastain (Vector Laboratories, Peterborough, Cambridgeshire, UK) followed by incubation with goat polyclonal anti-human IL-17 antibody (diluted 1 100 in blocking serum) at room temperature in a humidified chamber.
After non-specific binding was blocked by rabbit serum, the slides were incubated with the culture supernatant of the hybridoma producing the anti-H3.5 monoclonal antibody (1 100 dilution) for 24 h at room temperature, and endogenous H3.5 was visualized using the avidin biotin complex method.
After washing, non-specific binding was blocked with Aurion-BSA (Aurion, Wageningen, Netherlands).
After antigen retrieval, nonspecific binding was blocked for 30 min with 3% donkey serum in PBS.
After deparaffinisation and rehydration, unspecific binding was blocked.
After deparaffination and rehydration, nonspecific binding was blocked with Power Block (Biogenex, San Ramon, CA).
